Skip to main content
. 2023 Aug 5;5(10):100707. doi: 10.1016/j.xkme.2023.100707

Figure 1.

Figure 1

Before vs After Biopsy Clinician Ratings of Biopsy’s Impact on Clinical Management.a,b Abbreviations: CKD, chronic kidney disease; AKI, acute kidney injury. aWilcoxon signed-rank tests: Overall P < 0.001; CKD P < 0.001; AKI P = 0.30; bBefore biopsy, the Likert scale is: (1) extremely unlikely, (2) somewhat unlikely, (3) neither likely nor unlikely, (4) somewhat likely, and (5) extremely likely. After biopsy the Likert scale is: (1) very much not affected, (2) somewhat not affected, (3) neither affected nor not affected, (4) somewhat affected, and (5) very much affected.